Citadel Advisors’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.4M | Sell |
122,500
-16,500
| -12% | -$1.79M | ﹤0.01% | 2695 |
|
|
2026
Q1 | $12.8M | Sell |
139,000
-38,600
| -22% | -$3.88M | ﹤0.01% | 2891 |
|
|
2025
Q4 | $18.1M | Sell |
177,600
-12,800
| -7% | -$1.15M | ﹤0.01% | 2481 |
|
|
2025
Q3 | $11.9M | Buy |
190,400
+61,900
| +48% | +$3.37M | ﹤0.01% | 3004 |
|
|
2025
Q2 | $6.69M | Sell |
128,500
-71,600
| -36% | -$3.2M | ﹤0.01% | 3626 |
|
|
2025
Q1 | $8.52M | Buy |
200,100
+64,300
| +47% | +$2.77M | ﹤0.01% | 3070 |
|
|
2024
Q4 | $4.15M | Buy |
135,800
+45,000
| +50% | +$1.27M | ﹤0.01% | 4272 |
|
|
2024
Q3 | $2.08M | Buy |
90,800
+24,600
| +37% | +$696K | ﹤0.01% | 5452 |
|
|
2024
Q2 | $1.91M | Sell |
66,200
-814,600
| -92% | -$19M | ﹤0.01% | 5408 |
|
|
2024
Q1 | $18.2M | Buy |
880,800
+810,100
| +1,146% | +$17.4M | ﹤0.01% | 2177 |
|
|
2023
Q4 | $1.91M | Buy |
70,700
+18,600
| +36% | +$488K | ﹤0.01% | 5442 |
|
|
2023
Q3 | $1.54M | Buy |
52,100
+6,600
| +15% | +$232K | ﹤0.01% | 5701 |
|
|
2023
Q2 | $1.63M | Sell |
45,500
-36,600
| -45% | -$1.05M | ﹤0.01% | 5533 |
|
|
2023
Q1 | $1.92M | Sell |
82,100
-126,200
| -61% | -$3.6M | ﹤0.01% | 5461 |
|
|
2022
Q4 | $5.67M | Sell |
208,300
-228,000
| -52% | -$10.4M | ﹤0.01% | 3647 |
|
|
2022
Q3 | $23.5M | Buy |
436,300
+115,400
| +36% | +$5.92M | 0.01% | 1720 |
|
|
2022
Q2 | $12.9M | Buy |
320,900
+66,100
| +26% | +$3.28M | ﹤0.01% | 2357 |
|
|
2022
Q1 | $16.9M | Buy |
254,800
+50,200
| +25% | +$3.44M | ﹤0.01% | 2197 |
|
|
2021
Q4 | $20.5M | Buy |
204,600
+52,200
| +34% | +$5.4M | ﹤0.01% | 1988 |
|
|
2021
Q3 | $19.1M | Buy |
152,400
+56,800
| +59% | +$6.75M | ﹤0.01% | 2070 |
|
|
2021
Q2 | $11.9M | Sell |
95,600
-12,100
| -11% | -$1.63M | ﹤0.01% | 2818 |
|
|
2021
Q1 | $16.4M | Buy |
107,700
+21,800
| +25% | +$3.29M | ﹤0.01% | 2225 |
|
|
2020
Q4 | $11.1M | Sell |
85,900
-68,100
| -44% | -$7.84M | ﹤0.01% | 2505 |
|
|
2020
Q3 | $17.2M | Buy |
154,000
+92,800
| +152% | +$8.49M | ﹤0.01% | 1697 |
|
|
2020
Q2 | $4.96M | Sell |
61,200
-11,000
| -15% | -$886K | ﹤0.01% | 3091 |
|
|
2020
Q1 | $5.03M | Sell |
72,200
-9,600
| -12% | -$737K | ﹤0.01% | 2697 |
|
|
2019
Q4 | $6.39M | Sell |
81,800
-12,900
| -14% | -$930K | ﹤0.01% | 2778 |
|
|
2019
Q3 | $6.04M | Buy |
94,700
+22,600
| +31% | +$1.99M | ﹤0.01% | 2848 |
|
|
2019
Q2 | $6.22M | Buy |
72,100
+49,000
| +212% | +$3.74M | ﹤0.01% | 2779 |
|
|
2019
Q1 | $1.77M | Buy |
+23,100
| New | +$1.28M | ﹤0.01% | 4666 |
|
Other funds holding GH
DTC
Citadel Advisors's GH Position: Q2 2026 in Review
Citadel Advisors increased its Guardant Health (GH) stake by 87% in Q2 2026, buying an estimated $73.3M and bringing the position to 1,449,534 shares worth $217M. The position accounts for 0.02% of the portfolio, ranked #518.
Citadel Advisors first reported a position in GH in Q1 2019 and has held it in 29 quarters since. 598 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Citadel Advisors held 1,449,534 shares of Guardant Health worth $217M as of Q2 2026.
- Citadel Advisors bought 673,593 Guardant Health shares in Q2 2026, an estimated $73.3M.
- Guardant Health made up 0.02% of Citadel Advisors's portfolio in Q2 2026, its #518 holding.
- Citadel Advisors first reported a position in Guardant Health in Q1 2019 and has held it in 29 quarters since.
- 598 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.